Pan-cancer analysis identifies BIRC5 as a prognostic biomarker.
Pan-cancer analysis identifies BIRC5 as a prognostic biomarker.
复制标题
DOI：
10.1186/s12885-022-09371-0
复制
发表时间：
2022-03-25
期刊：
影响因子：
3.8
通讯作者：
Parris TZ
中科院分区：
文献类型：
--
作者：
Fäldt Beding A;Larsson P;Helou K;Einbeigi Z;Parris TZ
BIRC5基因编码Survivin蛋白，该蛋白是凋亡抑制家族的一员。生存素存在于人类胎儿发育期间，但在此后的成人细胞中通常不存在。先前的研究表明，Survivin在大多数癌细胞中含量丰富，因此使其成为抗癌药物的一个有希望的靶点和潜在的预后工具。为了评估BIRC5基因的遗传改变和突变以及BIRC5与其他基因的共表达，通过cbiopportal下载了来自癌症基因组图谱（TCGA）的约9000个样本的基因组和转录组数据，这些样本代表33种不同的癌症类型和11种泛癌症器官系统，并使用ICGC数据门户和COSMIC进行了验证。从Broad GDAC Firehose下载了来自33种不同癌症类型的TCGA BIRC5 RNA测序数据和16种癌症类型的匹配正常组织样本，并使用我们之前工作中的乳腺癌微阵列数据和基于web的GENT2工具的数据集进行验证。采用多变量Cox比例风险回归分析对生存数据进行分析，并使用KM绘图仪对乳腺癌、卵巢癌、肺癌和胃癌进行验证。虽然BIRC5的基因改变在癌症中并不常见，但在16种不同类型的癌症中，BIRC5在癌症组织中的表达明显高于正常组织。对于14/33种癌症类型，较高的BIRC5表达与较差的总生存率相关（调整年龄和肿瘤分级后的OS为4/14，仅调整年龄后的OS为10/14）。有趣的是，在肺鳞状细胞癌和卵巢浆液性囊腺癌中，较高的BIRC5表达与更好的OS相关。在14/33种癌症类型中，较高的BIRC5表达也与较短的无进展间期（PFI）相关（在调整年龄和肿瘤分级后为4/14，仅调整年龄后为10/14）。外部验证表明，高BIRC5表达与乳腺癌、肺癌和胃癌的不良OS显著相关。我们的研究结果表明，BIRC5过表达与几种癌症类型的发生和进展有关，因此是一种有希望的预后生物标志物。在线版本包含补充材料，可在10.1186/s12885-022-09371-0获得。
The BIRC5 gene encodes for the Survivin protein, which is a member of the inhibitor of apoptosis family. Survivin is found in humans during fetal development, but generally not in adult cells thereafter. Previous studies have shown that Survivin is abundant in most cancer cells, thereby making it a promising target for anti-cancer drugs and a potential prognostic tool. To assess genetic alterations and mutations in the BIRC5 gene as well as BIRC5 co-expression with other genes, genomic and transcriptomic data were downloaded via cBioPortal for approximately 9000 samples from The Cancer Genome Atlas (TCGA) representing 33 different cancer types and 11 pan-cancer organ systems, and validated using the ICGC Data Portal and COSMIC. TCGA BIRC5 RNA sequencing data from 33 different cancer types and matching normal tissue samples for 16 cancer types were downloaded from Broad GDAC Firehose and validated using breast cancer microarray data from our previous work and data sets from the GENT2 web-based tool. Survival data were analyzed with multivariable Cox proportional hazards regression analysis and validated using KM plotter for breast-, ovarian-, lung- and gastric cancer. Although genetic alterations in BIRC5 were not common in cancer, BIRC5 expression was significantly higher in cancer tissue compared to normal tissue in the 16 different cancer types. For 14/33 cancer types, higher BIRC5 expression was linked to worse overall survival (OS, 4/14 after adjusting for both age and tumor grade and 10/14 after adjusting only for age). Interestingly, higher BIRC5 expression was associated with better OS in lung squamous cell carcinoma and ovarian serous cystadenocarcinoma. Higher BIRC5 expression was also linked to shorter progressive-free interval (PFI) for 14/33 cancer types (4/14 after adjusting for both age and tumor grade and 10/14 after adjusting only for age). External validation showed that high BIRC5 expression was significantly associated with worse OS for breast-, lung-, and gastric cancer. Our findings suggest that BIRC5 overexpression is associated with the initiation and progression of several cancer types, and thereby a promising prognostic biomarker. The online version contains supplementary material available at 10.1186/s12885-022-09371-0.
登录
查看更多内容
影响因子：
7.3
作者：
Gao J;Aksoy BA;Dogrusoz U;Dresdner G;Gross B;Sumer SO;Sun Y;Jacobsen A;Sinha R;Larsson E;Cerami E;Sander C;Schultz N
通讯作者：
Schultz N
DOI：
10.2147/btt.s83864
发表时间：
2015
期刊：
Biologics : targets & therapy
影响因子：
--
作者：
Khan S;Ferguson Bennit H;Asuncion Valenzuela MM;Turay D;Diaz Osterman CJ;Moyron RB;Esebanmen GE;Ashok A;Wall NR
通讯作者：
Wall NR
影响因子：
4.8
作者：
de Moraes, Gabriela Nestal;Delbue, Deborah;Maia, Raquel C.
通讯作者：
Maia, Raquel C.
DOI：
10.4103/0971-5916.159250
发表时间：
2015-04
期刊：
The Indian journal of medical research
影响因子：
--
作者：
Jaiswal PK;Goel A;Mittal RD
通讯作者：
Mittal RD
影响因子：
2
作者：
Kim, Yoon Jung;Hwang, Hyo-Jeong;Lee, Seong Jin
通讯作者：
Lee, Seong Jin